HIF1A and hepatocellular carcinoma: Sustained anti-angiogenesis therapy increases the level of tumor hypoxia, leading to increased expression of HIF-1a, which promotes the production of pro-angiogenesis genes, thereby contributing to the resistance of HCC cells to anti-angiogenesis therapy [7].